Hill Stephen J. sold $1K of LYEL
Hill Stephen J. (Chief Operating Officer) sold 89 shares of Lyell Immunopharma, Inc. (LYEL) at $14.34 on 2026-08-10.
How this was made
The 30-second read
Why it matters
A COO open-market sale of 89 shares at $14.34 is disclosed; no new guidance, trial result, deal, or regulatory action is mentioned.
Market read
Traders may note the insider sale for sentiment, but the disclosed value is small and does not introduce new fundamental catalysts.
What to watch
Insider sales can be driven by tax, diversification, or pre-existing personal liquidity needs; without context on total holdings or prior sales, signal quality is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Lyell Immunopharma, Inc.
Ticker impact
Lyell Immunopharma COO Stephen J. Hill sold 89 shares at $14.34 on 2026-08-10, totaling $1,276.26, per Form 4.
Low likelihood of a sustained price move; any reaction would likely be brief and limited to intraday sentiment.
The transaction size is small ($1.3k) and the filing provides no new company-specific operational or financial information.
Market effects
No clear sector read-through from a small insider sale at a single biotech name.
None indicated.
None indicated.
Counterpoint
The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, but the dollar amount is too small to be a strong signal.
Key entities
- issuerLyell Immunopharma, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderStephen J. Hill
Chief Operating Officer who sold 89 shares.